New results from the phase 3 CREST trial have shown that the combination of sasanlimab and bacillus Calmette-Guérin (BCG) provides a significant improvement for patients with BCG-naive, high-risk (HR) non-muscle invasive bladder cancer (NMIBC) over BCG alone. The study met its primary endpoint of event-free survival (EFS) for the combination induction therapy, which had a safety profile consistent with data reported from previous clinical trials of the two treatments. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Dr. Neal Shore reviews the history of nadofaragene firadenovec in high-risk disease, and the anticipated outcomes of ABLE-32.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Advertisement
Advertisement
Latest News
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.